Results 41 to 50 of about 35,525 (153)

Impact of SGLT2 inhibitors treatment on the chronic kidney disease in people with type 2 diabetes

Journal of Education, Health and Sport, 2022
Diabetes is the most common cause of CKD (chronic kidney disease). CKD is also one of the most important diabetic complication. SGLT2 (sodium glucose co‐transporter‐2) inhibitors are new class of medication used to lower high blood glucose level in ...
Marcin Czarkowski, Karolina Raksa, Ewelina Powroźniak, Karol Spozowski   +3 more
doaj   +1 more source

Use of sodium glucose co‐transporter 2 inhibitors in acute heart failure: a practical guidance

ESC Heart Failure, 2022
Aims Heart failure (HF) is the most frequent cause of hospital admission among patients 65 years or older. Patients hospitalized for acutely decompensated chronic HF and ‘de novo’ acute heart failure (AHF) continue to experience unacceptably high post ...
João Pedro Ferreira, Joana Pimenta, Brenda Moura, Carlos Aguiar, Fátima Franco   +4 more
doaj   +1 more source

A case report of euglycemic ketoacidosis due to dapagliflozin treatment

Turkish Journal of Internal Medicine, 2021
Diabetic ketoacidosis (DKA) is a leading cause of mortality and morbidity in type 2 diabetic patients. Sodium-glucose co-transporter (SGLT-2) inhibitors are a new antidiabetic treatment class that increases the renal excretion of glucose.
Murat Çalapkulu, Muhammed Erkam Sencar, İlknur Öztürk Ünsal, Hayri Bostan, Erman Çakal   +4 more
doaj   +1 more source

Robustness of outcomes in trials evaluating sodium–glucose co‐transporter 2 inhibitors for heart failure

ESC Heart Failure, 2022
Aims Recent trials have evaluated sodium–glucose co‐transporter 2 inhibitors in patients with heart failure (HF). We sought to assess the robustness of findings from these trials using the fragility index (FI).
Muhammad Shariq Usman, Muhammad Shahzeb Khan, Gregg C. Fonarow, Stephen J. Greene, Tim Friede, Muthiah Vaduganathan, Gerasimos Filippatos, Andrew J. Stewart Coats, Stefan D. Anker, Javed Butler   +9 more
doaj   +1 more source

Inhibitors of sodium-glucose transport protein 2: A new multidirectional therapeutic option for heart failure patients

Cardiology Journal, 2023
Several mechanisms have been suggested to explain positive cardiovascular effects observed in studies with sodium-glucose co-transporter 2 (SGLT2) inhibitors.
Jacek Kubica, Aldona Kubica, Klaudyna Grzelakowska, Wioleta Stolarek, Zofia Grąbczewska, Piotr Michalski, Piotr Niezgoda, Stanisław Bartuś, Andrzej Budaj, Mariusz Dąbrowski, Jarosław Drożdż, Ryszard Gellert, Miłosz J. Jaguszewski, Piotr Jankowski, Jacek Legutko, Maciej Lesiak, Przemysław Leszek, Jolanta Małyszko, Przemysław Mitkowski, Jadwiga Nessler, Krzysztof Pawlaczyk, Jolanta Siller-Matula, Tomasz Stompór, Bogumił Wolnik, Eliano Pio Navarese   +24 more
doaj   +1 more source

Empagliflozin Improves Diastolic Function in a Nondiabetic Rodent Model of Heart Failure With Preserved Ejection Fraction

JACC: Basic to Translational Science, 2019
Summary: Recent studies send an unambiguous signal that the class of agents known as sodium-glucose–linked co-transporter-2 inhibitors (SGLT2i) prevent heart failure hospitalization in patients with type 2 diabetes. However, the mechanisms remain unclear.
Kim A. Connelly, MBBS, PhD, Yanling Zhang, MD, Aylin Visram, BSc, Andrew Advani, BSc, MBChB, PhD, Sri N. Batchu, PhD, Jean-François Desjardins, MSc, Kerri Thai, BSc, Richard E. Gilbert, MBBS, PhD   +7 more
doaj   +1 more source

Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary

Frontiers in Cardiovascular Medicine, 2022
A new therapeutic class of oral agents firstly used for the treatment of type 2 diabetes mellitus is represented by gliflozines or sodium-glucose co-transporter 2 (SGLT2) inhibitors.
Annamaria Mascolo, Annamaria Mascolo, Raffaella Di Napoli, Raffaella Di Napoli, Nunzia Balzano, Nunzia Balzano, Donato Cappetta, Konrad Urbanek, Konrad Urbanek, Antonella De Angelis, Lucia Scisciola, Irene Di Meo, Maria Giuseppa Sullo, Maria Giuseppa Sullo, Concetta Rafaniello, Concetta Rafaniello, Liberata Sportiello, Liberata Sportiello   +17 more
doaj   +1 more source

Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure

Frontiers in Cardiovascular Medicine, 2021
Heart failure (HF) is a common complication or late-stage manifestation of various heart diseases. Numerous risk factors and underlying causes may contribute to the occurrence and progression of HF.
Qingchun Zeng, Qingchun Zeng, Qingchun Zeng, Qing Zhou, Qing Zhou, Weitao Liu, Yutong Wang, Xingbo Xu, Dingli Xu, Dingli Xu, Dingli Xu   +10 more
doaj   +1 more source

Sodium-glucose co-transporter-2 inhibitors and euglycemic ketoacidosis: Wisdom of hindsight

Indian Journal of Endocrinology and Metabolism, 2015
Sodium-glucose co-transporter-2 inhibitors (SGLT-2i) are newly approved class of oral anti-diabetic drugs, in the treatment of type 2 diabetes, which reduces blood glucose through glucouresis via the kidney, independent, and irrespective of available ...
Awadhesh Kumar Singh
doaj   +1 more source

Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review

Hormone Research in Paediatrics, 2022
<b><i>Background:</i></b> With recent developments in diabetes technology, attaining adequate glucose control is more achievable than ever. Despite these improvements, a significant proportion of individuals with type 1 diabetes do not reach recommended glycaemic goals.
Tim Hropot, Tadej Battelino, Klemen Dovc
openaire   +3 more sources